SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $1.00 target price on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 1.01% from the stock’s current price.

According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “

Shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ SBMFF) opened at 0.99 on Thursday. SINO BIOPHARMACEUT HKD0.025 has a 1-year low of $0.64 and a 1-year high of $0.99. The company has a market cap of $7.34 billion and a P/E ratio of 25.38. The stock’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.82.

TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at

Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with's FREE daily email newsletter.